Loading stock data…
$7.80+0.36 (+4.77%)
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Verastem, Inc. in the Healthcare sector is trading at $7.80 with a market capitalization of $596M. Wall Street consensus targets $15.00 (9 analysts), implying a +92.2% move over the next 12 months. The stock is currently 28% below its 52-week high of $10.82, remaining 29.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.08M↑ | $18.67M↑ | $17.54M↑ | $11.24M↑ | $2.14M |
| Gross Profit | $36.04M↑ | $15.62M↑ | $14.64M↑ | $9.28M↑ | $1.69M |
| Operating Income | -$32.71M↑ | -$44.90M↓ | -$41.48M↓ | -$40.72M↑ | -$43.76M |
| Net Income | -$34.67M↑ | -$36.59M↓ | -$32.92M↑ | -$98.52M↓ | -$25.93M |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule ...